

Acne Vulgaris Market Size to Reach USD 10.4 Billion by 2035 - Epidemiology Report by IMARC Group

The report provides a detailed analysis of the current acne vulgaris marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- The [acne vulgaris market size reached a value of USD 7.2 billion](#) in 2024.

Looking forward, IMARC Group expects the 7MM to reach USD 10.4 billion by 2035, exhibiting a growth rate (CAGR) of 3.33% during 2025-2035.

Acne vulgaris is a common chronic inflammatory skin disease, affecting a large percentage of the world's population at some stage in their lives, mostly adolescents and young adults. It is estimated to occur in 9.4% of the world's population, with prevalence up to 80-90% in teenagers and 40-50% in adults in their twenties and thirties. Aside from its physical forms, acne also causes permanent scarring and significant psychological distress, such as depression and anxiety, which highly encourage individuals to acquire effective treatments. Acne's strong psychological consequence, going beyond physical discomfort, is a strong driver for market expansion.

It implies that demand is greatly driven by quality of life and self-esteem, not just by medical issues. Those firms which successfully make inroads on this emotional aspect of their product planning and promotion, with a goal of "completely clear skin" or riding awareness campaigns, are ready to gain considerable market share. This also reflects a transition in consumer demands from the management of symptoms to esthetic excellence and better mental health. In addition, the growing incidence of acne in adults, in conjunction with widespread increases in aesthetic concerns, broadens the target audience for the market beyond the teenage years. This creates an escalating demand for products that will address dual action, i.e., acne treatment and anti-aging, or be specific to the needs of older skin, which suggests a need for ongoing treatment solutions over a longer life course. Key Trends Shaping the Market in 2025 2025 will witness



ongoing innovation in therapies targeting the root causes of acne specifically.

One strong trend is the emergence of next-generation laser therapies, especially the 1726-nm sebum-targeting lasers such as AviClear and Accure, which provide targeted intervention for inflammatory acne with good results and low side effects.

These technologies are a strategic shift towards non-invasive and minimally invasive treatments that minimize scarring and downtime, pleasing patients who want effective but convenient treatments. Aside from lasers, the market is seeing the creation of innovative pharmacologic therapies, such as new topical and oral compounds that work against resistant bacterial strains, and biologic drugs for more serious, chronic inflammatory conditions. The release of certain drugs such as clascoterone cream, which gained regulatory clearances during early 2025, is an example of emphasis on targeted action, anti-inflammatory action, and lower risk of antibiotic resistance. There is also more research into add-on treatments such as probiotics and immunomodulators that seek to re-establish microbial balance of the skin.

Request for a sample of this report: <https://www.imarcgroup.com/acne-vulgaris-market/requestsampl>

This report also provides a detailed analysis of the current acne vulgaris marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the acne vulgaris market has been studied in the report with the detailed profiles of the key players operating in the market.

Ortho Dermatologics
Galderma/Mayne Pharma
Almirall S.A./Paratek Pharmaceuticals
Stiefel Laboratories
Cosmo Pharmaceuticals
Biofrontera Inc. (BFRI)
Novan
AOBiome LLC
Botanix Pharmaceuticals
AndroScience Corporation

Buy the full Acne Vulgaris Market Epidemiology Report with TOC:
<https://www.imarcgroup.com/checkout?id=6892&method=809>

7 Major Countries Covered:

United States
Germany
France
United Kingdom
Italy
Spain
Japan

IMARC Group Offers Other Reports:

Achromatopsia Market Epidemiology Report 2025-2035: <https://www.cmswire.com/the-wire/achromatopsia-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales-and-regional-outlook/>

Apraxia Market Epidemiology Report 2025-2035: <https://www.cmswire.com/the-wire/apraxia-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales-and-regional-outlook/>

Cancer Cachexia Market Epidemiology Report 2025-2035: <https://www.cmswire.com/the-wire/cancer-cachexia-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales-and-regional-outlook/>

Choroideremia Market Epidemiology Report 2025-2035: <https://www.cmswire.com/the-wire/choroideremia-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales-and-regional-outlook/>

Hypophosphatasia Market Epidemiology Report 2025-2035: <https://www.cmswire.com/the-wire/hypophosphatasia-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales->

[and-regional-outlook/](#)

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/830574882>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.